CPC C07K 14/005 (2013.01) [A61K 39/12 (2013.01); A61P 31/14 (2018.01); B82Y 5/00 (2013.01); C12N 7/00 (2013.01); A61K 2039/575 (2013.01); C07K 2319/735 (2013.01); C12N 2760/18022 (2013.01); C12N 2760/18322 (2013.01); C12N 2760/18522 (2013.01)] | 30 Claims |
1. A nanostructure, comprising:
(a) a plurality of first assemblies, each first assembly comprising a plurality of identical first polypeptides, wherein the first polypeptides comprise polypeptides having at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to the amino acid sequence of a polypeptide selected from the group consisting of SEQ ID NOS:1-51;
(b) a plurality of second assemblies, each second assembly comprising a plurality of identical second polypeptides, wherein the second polypeptides comprise polypeptides having at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to the amino acid sequence of a polypeptide selected from the group consisting of SEQ ID NOS:1-51,
wherein the second polypeptide differs from the first polypeptide;
wherein the plurality of first assemblies non-covalently interact with the plurality of second assemblies to form a nanostructure; and
wherein the nanostructure displays multiple copies of one or more paramyxovirus and/or pneumovirus F proteins, or antigenic fragments thereof, on an exterior of the nanostructure.
|